Dexcom (DXCM) Long-Term Debt Repayments (2013 - 2023)

Dexcom (DXCM) reported Long-Term Debt Repayments of $136.8 million for Q4 2023, up 82.4% quarter-over-quarter from $75.0 million in Q2 2017.

Dexcom (DXCM) Long-Term Debt Repayments (2013 - 2023) Analysis & Trends

Dexcom (DXCM) has 6 years of Long-Term Debt Repayments data on file, last reported at $136.8 million in Q4 2023.

Long-Term Debt Repayments for Q4 2023 came in at $136.8 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was $136.8 million (changed 0.0% YoY), and the FY2023 annual result was $787.3 million, changed N/A from the prior year.
Long-Term Debt Repayments rose to $136.8 million in Q4 2023 per DXCM's latest filing, from $75.0 million in the prior quarter.
Over five years, Long-Term Debt Repayments peaked at $136.8 million in Q4 2023 and troughed at $136.8 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn	1.42 Bn
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn	1.00 Bn
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn	-
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn	-
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn	-
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	-
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn	-
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn	-
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn	-
10	Zimmer Biomet Holdings	17.18 Bn	16.77 Bn	1.51 Bn	-

Download Data